Iradimed (NASDAQ:IRMD - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.410-0.440 for the period, compared to the consensus estimate of 0.440. The company issued revenue guidance of $19.7 million-$19.9 million, compared to the consensus revenue estimate of $19.8 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.
Iradimed Price Performance
Shares of NASDAQ:IRMD traded down $0.88 during midday trading on Friday, reaching $51.79. 24,445 shares of the company's stock were exchanged, compared to its average volume of 43,511. The firm's 50 day simple moving average is $52.10 and its two-hundred day simple moving average is $54.34. Iradimed has a fifty-two week low of $41.60 and a fifty-two week high of $63.29. The stock has a market cap of $658.51 million, a price-to-earnings ratio of 34.53 and a beta of 0.91.
Iradimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.05). Iradimed had a return on equity of 24.12% and a net margin of 26.26%. The company had revenue of $19.39 million during the quarter, compared to analyst estimates of $19.09 million. Equities research analysts predict that Iradimed will post 1.66 earnings per share for the current fiscal year.
Iradimed Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 30th. Stockholders of record on Tuesday, May 20th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.31%. Iradimed's payout ratio is presently 43.87%.
Wall Street Analyst Weigh In
Several research firms have recently commented on IRMD. Roth Mkm reissued a "buy" rating and issued a $72.00 price objective (up previously from $60.00) on shares of Iradimed in a research note on Friday, February 14th. StockNews.com upgraded shares of Iradimed from a "buy" rating to a "strong-buy" rating in a research note on Tuesday.
Read Our Latest Stock Report on IRMD
About Iradimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Stories
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
